

Transcutaneous posterior tibial nerve stimulation versus extended release oxybutynin in overactive bladder patients. A prospective randomized trial



Valentín Manríquez^{a,*}, Rodrigo Guzmán^a, Michel Naser^a, Amalia Aguilera^a,
Simonie Narvaez^a, Ariel Castro^b, Steven Swift^c, G. Alessandro Digesu^d

^a Pelvic Floor Unit, Obstetrics and Gynecology Department, Clinical Hospital, Universidad de Chile, Chile

^b Clinical Investigation Support Department, Clinical Hospital, Universidad de Chile, Chile

^c Division of Urogynecology & Incontinence, Medical University of South Carolina, United States

^d Imperial College Healthcare NHS Trust, Academic Department of Obstetrics & Gynaecology, United Kingdom

ARTICLE INFO

Article history:

Received 3 April 2015

Received in revised form 2 September 2015

Accepted 17 September 2015

Keywords:

Neuromodulation
Overactive bladder
Quality of life

ABSTRACT

Introduction and hypothesis: The aim of this study was to evaluate the effectiveness of transcutaneous posterior tibial nerve stimulation (T.C. PTNS) versus extended release oxybutynin (E.R.O.) in patients with overactive bladder.

Materials and methods: Seventy female patients were randomized to receive either 10 mg E.R.O. daily or T.C. PTNS, using a TENS machine program with the 20 Hz, 200 cycles/s, and normal stimulation setting for two 30-min sessions, each week for a 12-week period. Pre-treatment and after the 12-week intervention, each patient completed a 3-day voiding diary and a self-report quality of life questionnaire (OAB-q). Statistical analysis was performed using Stata V12.1.

Results: Sixty-four patients completed the treatment protocol. There were no significant differences between study groups in terms of age, body mass index, past hormone replacement therapy, smoking habits, menopause status, and parity. Prior to treatment, there were also no significant differences in the analysis of the 3-day voiding diary or in the OAB-q questionnaire results. Following the 12-week study, there was a statistically significant reduction in frequency of urination, urgency episodes, and urge incontinent episodes compared to pre-treatment values. However, there were no significant differences in these values between intervention groups after 12-weeks of therapy. There was a similar improvement in OAB-q scores in both treatment groups following therapy, and the T.C. PTNS group showed a statistically significant improvement over the E.R.O. in domain 2 of the OAB-q questionnaire. The other two domains showed similar improvement in both study groups.

Conclusion: T.C. PTNS and E.R.O. demonstrated similar improvements in subjects with OAB in a 12-week study.

© 2015 Published by Elsevier Ireland Ltd.

Brief summary

Transcutaneous posterior tibial nerve stimulation is as effective as extended release oxybutynin as a treatment option to control overactive bladder symptoms and improve patient quality of life.

Introduction

Overactive bladder syndrome (OAB) is a common and debilitating condition that is increasingly seen by gynecologists, as a result of growing patient awareness, improved understanding of the condition, the introduction of new treatment modalities, patients' increased desire for improved quality of life, and changing demographics, as the global population ages. The condition is defined by the International Continence Society (ICS) as "urgency, with or without urge incontinence, usually with frequency and nocturia, in the absence of local or metabolic factors explaining these symptoms" [1]. Although the exact prevalence of OAB is unknown, since investigators have used varied definitions of OAB in epidemiologic studies and clinical trials, two large

* Corresponding author at: Hospital Clínico Universidad de Chile, Santos Dumont 999 oficina 209-A, Independencia, Santiago, Chile. Tel.: +56 22297882879; mobile: +56 984391865.

E-mail address: valentinmanriquez@gmail.com (V. Manríquez).

population-based surveys using the 2010 ICS definition for OAB have reported prevalences of 9.4% and 16.9% [2,3]. Extrapolated to the population in Chile, where the current study was conducted, nearly 2 million adults could suffer from OAB. With demographic changes, gynecologists can expect to see an even greater number of individuals seeking medical attention, for OAB symptoms in the future.

Pharmacotherapy has long been the mainstay for OAB treatment, and a variety of newer drugs have recently been introduced. These drugs – anticholinergic/muscarinic receptor antagonists – have demonstrated efficacy, with varying dosing schedules, side-effect profiles, and biochemical properties. Gopal et al. studied the discontinuation rates of female patients treated with anticholinergic medication, due to concerns of poor tolerability or suboptimal success rates. The authors found that the average 6-month incidence of discontinuation was 58.8%, with discontinuation rates ranging from 54% to 71%, depending on the medication used [4]. Moreover, a study by Kay et al. has shown that 30% of OAB patients do not respond to antimuscarinics, and that there are often several co-morbidities that prevent the use of this class of drug [5].

In light of the above, there is a growing need for therapeutic options that are as effective as antimuscarinics, but which have fewer side effects and contraindications and are available at a lower cost. Since 1999, posterior tibial nerve stimulation (PTNS) has had demonstrated efficacy in controlling symptoms and improving quality of life in OAB patients, with approximately 70% of patients achieving at least a 50% reduction in incontinence episodes, and with 40–50% achieving complete dryness [6]. A few trials have compared the effectiveness of PTNS and antimuscarinic drugs, showing similar responses for both treatments [7]. Traditional PTNS treatment, however, is costly and requires direct professional supervision for the placement of needles.

Transcutaneous tibial nerve stimulation (T.C. PTNS), on the other hand, uses a surface electrode, instead of a needle, to stimulate the nerve, making it a less expensive and less invasive treatment option, which could be self-applied by patients. Recently, research has shown that T.C. PTNS has proven to be an effective treatment option in managing refractory OAB patients [8]. Nevertheless, to our knowledge, there are no published trials comparing the effectiveness of T.C. PTNS versus antimuscarinic drugs for patients with OAB.

The aim of our study was to compare the effectiveness of transcutaneous posterior tibial nerve stimulation (T.C. PTNS) versus extended release oxybutynin (E.R.O.), an antimuscarinic drug, in OAB symptom control and quality of life improvement.

Materials and methods

Between November 2010 and December 2013, 70 female patients recruited from the Pelvic Unit of the Clinical Hospital of Universidad de Chile in Santiago were randomized by permuted blocks to either 10 mg E.R.O. daily or twice a week T.C. PTNS. T.C. PTNS was applied using a TENS machine program, with 20 Hz, 200 cycles/s normal stimulation for 30 min each session, and voltage was regulated by patients, each time they achieved motor response (plantar flexion of the big toe and/or toe fanning) (Fig. 1). As previously reported [9], the more frequent the stimulation, the earlier the clinical response. Although stimulation could, ideally, be performed daily, the study participants had to travel to the hospital for applications of T.C. PTNS, to ensure that stimulation was applied in concordance with protocol. Thus, to reduce subjects financial burden, and prevent drop-out, yet still receive an earlier response than would be seen by once a week stimulation, we decided to apply T.C. PTNS twice a week.

Primary outcomes were the results of a 3-day voiding diary and the results of the OAB-q questionnaire. Each participant completed a 3-day voiding diary, which recorded urinary frequency, urgency episodes, and urge incontinence episodes, and filled out the OAB-q self-report questionnaire before randomization and at the end of the 12-week intervention period. The OAB-q questionnaire is a quality of life questionnaire, developed to assess symptom bother and health-related quality of life (HRQL) among patients with either continent or incontinent overactive bladder. It has an 8-item symptom bother scale and four HRQL subscales (coping, concern, sleep, and social interaction), which are derived from 25 items. Successful responders were defined as participants who demonstrated a $\geq 50\%$ reduction in urinary frequency, based on the 3-day voiding diary, compared to pre-treatment values.

Inclusion criteria were the following: clinical diagnosis of OAB (as defined by IUGA/ICS 2010 guidelines), being 18 years of age or older permanent residence in the Metropolitan Region of Santiago for the subsequent 6 months, and having a negative urine culture within 2 weeks of randomization. Pregnant women, pacemaker users, and those whose symptoms were suspected to be neurological or inflammatory in origin were excluded.

In the E.R.O. group, 29 out of 34 patients, and 31 out of 36 patients in the T.C. PTNS group, were naive to treatment options regarding overactive bladder. Previously treated participants were asked to follow a 2-week wash-out period, if they were undergoing antimuscarinic treatment.

The study was approved by the local ethical committee of the Clinical Hospital of Universidad de Chile (IRB: 225/07), and written informed consent was obtained from all patients.

Sample size

The Arcsine method was used to calculate sample size, based on the assumption of E.R.O. achieving a 40% reduction in urinary frequency and T.C. PTNS a 70% reduction, with 5% alpha error and 20% beta error. The allocation ratio was 1:1, with a replacement rate of 5%, in the case of loss of participants to follow-up. A sample size of 70 participants was calculated.

Statistical analysis

Statistical analysis was conducted using Stata V12.1, licensed to author A. Castro. Data were presented with summary measures of central tendency (average and median) and dispersion (standard deviation and range).

The T-test and Wilcoxon test were used for continuous normally distributed and non-normally distributed data, respectively. Normality was checked using the Kolmogorov–Smirnov method, and the comparison test of proportions was also used. A p -value of <0.05 was considered statistically significant, with a 95% confidence interval (CI 95%).

Results

Of the 70 enrolled participants, 34 were randomized to receive 10 mg E.R.O., and 36 to T.C. PTNS. Four women in the antimuscarinic (E.R.O.) group were lost to follow-up, due to adverse effects (dry mouth) and pregnancy, and two women were lost to follow-up in the neuromodulation group (T.C. PTNS), one becoming pregnant and the other changing her city of residence (Fig. 1). No adverse events were reported in the T.C. PTNS group, while 9 patients in the E.R.O. group reported dry mouth. There were no significant differences between treatment groups in terms of age, body mass index, past hormone replacement therapy, smoking status, menopause status, and parity (Table 1).




Fig. 1. Flow of patients through the trial. * E.R.O.: extended release oxybutynin; ** T.C. PTNS: transcutaneous posterior tibial nerve stimulation.

Prior to treatment, there were no significant differences in the 3-day voiding diary variables or in the OAB-q questionnaire between groups (Table 2). There was a statistically significant improvement in both groups over baseline values for both voiding diary variables and OAB-q domains (Table 3). After the 12-week intervention period, it was found that 70% of patients in

the T.C. PTNS group versus 60% in the E.R.O. group had a successful response to treatment as defined by a $\geq 50\%$ reduction in urinary frequency. It was also noted that 25% and 13% of patients achieved dryness, with T.C. PTNS and E.R.O. respectively. These differences were not statistically significantly different between groups. There were also no significant differences in any of the voiding diary variables between treatment groups at the end of the intervention. However, there was a significant difference favoring T.C. PTNS in domain 2 of the of the OAB-q quality of life questionnaire (Table 4).

Table 1
Demographic characteristics.

	E.R.O. (34)	T.C. PTNS (36)	p-Value
^a Age (years)	53 (18–71)	54.5 (18–84)	0.56
^b BMI kg/m ²	27.8 (25.8–29.1)	27.4 (25.8–28.9)	0.47
^c HRT	31 (91.1%)	30 (88.2%)	0.5
	3 (8.8%)	4 (11.7%)	
Smoking habit	28 (82.3%)	28 (84.8%)	0.52
	6 (17.6%)	5 (15.1)	
Menopause	17 (50%)	14 (58.8%)	0.31
	17 (50%)	20 (58.8%)	
Parity	6 (17.6%)	6 (18.1%)	0.71
	4 (11.7%)	2 (6.1%)	
	24 (70.5%)	25 (75.7%)	

^a Average and range.

^b Average and CI 95%.

^c HRT = past use of hormone replacement therapy.

Table 2
Comparison between groups before treatment.

	E.R.O.	T.C. PTNS	p-Value
Frequency ^a	28 (0–55)	24 (12–48)	0.07
Urgency ^a	16 (0–47)	14 (0–49)	0.76
Urge incontinence ^a	3.5 (0–22)	5.5 (0–24)	0.32
Daily pads ^a	8.5 (0–36)	7.5 (0–19)	0.86
OAB-q domain 1 ^a	33.8 (31.0–36.7)	33.2 (30.8–35.6)	0.36
OAB-q domain 2 ^a	60.4 (54.3–66.5)	55.2 (49.5–60.9)	0.11
OAB-q domain 3 ^a	36.3 (32.2–40.4)	35.5 (31.5–39.5)	0.38

^a Median and range.

Table 3

Pre-treatment voiding diary and OAB-q scores compared with post-treatment in E.R.O. and T.C. PTNS groups.

	E.R.O. Pre	E.R.O. Post	p-Value
Frequency ^a	28 (11–55)	20.5 (9–44)	0.0011
Urgency ^a	16 (4–47)	4.5 (0–27)	0.0004
Urge incontinence ^a	4 (0–22)	0 (0–27)	0.0005
Daily pads ^a	9 (0–36)	0 (0–30)	0.001
OAB-q domain 1 ^a	33 (31–36)	18 (8–45)	0.0004
OAB-q domain 2 ^a	60 (54–66)	37 (17–79)	0.0002
OAB-q domain 3 ^a	36 (32–40)	23 (11–57)	0.0281
	T.C. PTNS Pre	T.C. PTNS Post	
Frequency ^a	24 (12–48)	18 (11–54)	0.0035
Urgency ^a	14 (0–49)	5 (0–15)	<0.001
Urge incontinence ^a	5 (0–24)	0 (0–30)	0.001
Daily pads ^a	7 (0–19)	2 (0–13)	0.0022
OAB-q domain 1 ^a	33 (30–35)	16 (10–46)	<0.001
OAB-q domain 2 ^a	55 (49–60)	30 (15–83)	<0.001
OAB-q domain 3 ^a	35 (31–39)	20 (10–51)	<0.001

^a Median and range.**Table 4**

Comparison between groups after treatment.

	E.R.O.	T.C. PTNS	p-Value
Frequency ^a	20 (16–3)	18 (15–22)	0.400
Urgency ^a	3 (0–9)	5 (1–10)	0.490
Urge incontinence ^a	0 (0–0)	0 (0–2)	0.232
Daily pads ^a	0 (0–8)	2 (0–6)	0.767
OAB-q domain 1 ^a	18.5 (8–45)	16.5 (10–46)	0.886
OAB-q domain 2 ^a	37.5 (17–79)	30.5 (15–83)	0.036
OAB-q domain 3 ^a	23 (11–57)	20.5 (10–51)	0.136

^a Median and range.

Comments

Percutaneous posterior tibial nerve stimulation (PTNS) has proven to be effective in the management of overactive bladder syndrome, significantly improving the quality of life of patients comparable to patients treated with anti-muscarinic extended release oxybutynin (E.R.O.) [10]. In addition to the clinical and urodynamic evidence of its success [11], PTNS has been demonstrated to produce modifications of the long latency somatosensory evoked potentials in the frontal cortex with repeated stimulation [12]. This observation explains the carry-over effect following a cycle of stimulation, in which patients report an extended clinical effect after initial treatment for a variable period of time. However, clinical efficacy was only maintained for longer than one year of follow-up in less than 22% of participants [13]. In fact, it has been shown that over a one-year period at least two, 12-week cycles are recommended to ensure sustained clinical effect for three months, on average [14].

Few studies have demonstrated the effect of transcutaneous (T.C. PTNS) in the treatment of patients with overactive bladder [8]. To our knowledge, this is the first trial to evaluate the effectiveness of T.C. PTNS in controlling patients' OAB symptoms and improving quality of life. The current study has demonstrated that T.C. PTNS has excellent efficacy in improving both objective and subjective measures in the treatment of OAB. The demonstrated efficacy is similar to the current gold standard of an extended release anti-muscarinic agent, suggesting that this therapy can be considered a first-line treatment.

This prospective randomized trial was designed to compare the effectiveness of T.C. PTNS against a well-known and effective antimuscarinic drug (E.R.O.). Evaluation was focused on the treatments associated clinical effects and quality of life improvement, rather than on patient's acceptance or adherence to

treatment. Unlike traditional PTNS, which requires a visit to a health care provider for placement of acupuncture needles, T.C. PTNS uses surface applied electrodes, that can be placed by patients themselves in their home setting, which could make this form of neuromodulation more acceptable to patients. Acceptability and satisfaction, however, were not measured in the current study and should be evaluated in future clinical trials.

Another benefit of T.C. PTNS is the low total associated cost, of approximately 45 euros, which includes the purchase of a TENS machine, surface electrodes, and a 6 V battery, making it a feasible treatment option for developing countries, with limited resources. In comparison, in our country the cost of the antimuscarinic therapy could reach in average 50 euros monthly. Additionally, T.C. PTNS could be used to avoid the adverse effects associated with antimuscarinic drugs, while achieving a proven clinical effect to manage OAB in diverse populations. We are currently conducting a study on the use of daily, self administer T.C. PTNS among elderly women and children with overactive bladder, which will provide new information on the effectiveness and long term effect of daily T.C. PTNS in different ages.

It is important to note that T.C. PTNS can be easily taught to patients or their families, as a self-administered therapy, which could be applied more frequently, without need for direct professional supervision, thereby further reducing the treatment's associated cost and the period of time needed to achieve a clinical effect. As demonstrated by Finazzi Agrò et al. [9], the more frequently stimulation is applied, the earlier a clinical response is achieved. In light of the aforementioned advantages of this treatment option, T.C. PTNS is recommended for patients with OAB, to improve both their clinical condition and their quality of life.

Conflict of interest

V. Manríquez and M. Naser have received support from J&J to attend IUGA and ICS meetings.

Author contributions

V. Manríquez: project development, data analysis, and manuscript writing; M. Naser: project development; R. Guzmán: manuscript editing; S. Narvaez and A. Aguilera: data collection; A. Castro: data management and analysis; S. Swift: manuscript editing; G.A. Digesu: manuscript editing.

References

- [1] Halen BT, de Ridder D, Freeman R, Swift S, Berghmans B, Lee J. An International Urogynecology Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. *Neurourol Urodyn* 2010;29:4–20.
- [2] Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. *Eur Urol* 2006;50(6):1306–15.
- [3] Stewart W, Van Rooyen J, Cundiff G, et al. Prevalence and burden of overactive bladder in the United States. *World J Urol* 2003;20(6):327–36.
- [4] Gopal M, Haynes K, Bellamy SL, Arya LA. Discontinuation rates of anticholinergic medications used for the treatment of lower urinary tract symptoms. *Obstet Gynecol* 2008;112(6):1311–8.
- [5] Kay GG, Abou-Donia MB, Messer WS, Murphy DG, Tsao JW, Ouslander JG. Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients. *J Am Geriatr Soc* 2005;53(12):2195–201.
- [6] Vandoninck V, van Balken MR, Agró EF, et al. Posterior tibial nerve stimulation in the treatment of urge incontinence. *Neurourol Urodyn* 2003;22(1):17–23.
- [7] Peters KM, MacDiarmid SA, Wooldridge LS, et al. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial. *J Urol* 2009;182(3):1055–61.
- [8] Ammi M, Chautard D, Brassart E, Culty T, Azzouzi AR, Bigot P. Transcutaneous posterior tibial nerve stimulation: evaluation of a therapeutic option in the management of anticholinergic refractory overactive bladder. *Int Urogynecol J* 2014;25(8):1065–9.

- [9] Finazzi AE, Campagna A, Scjobica F, et al. Posterior tibial nerve stimulation: is the once-a-week protocol the best option? *Minerva Urol Nefrol Ital J Urol Nephrol* 2005;57(2):119–23.
- [10] Van Der Pal F, Van Balken MR, Heesakkers JP, Debruyne FM, Kiemeny LA, Bemelmans BL. Correlation between quality of life and voiding variables in patients treated with percutaneous tibial nerve stimulation. *BJU Int* 2006;97(1):113–6.
- [11] Vandoninck V, van Balken MR, Finazzi Agrò E, et al. Posterior tibial nerve stimulation in the treatment of voiding dysfunction: urodynamic data. *Neurorol Urodyn* 2004;23(3):246–51.
- [12] Finazzi-Agrò E, Rocchi C, Pachatz C, et al. Percutaneous tibial nerve stimulation produces effects on brain activity: study on the modifications of the long latency somatosensory evoked potentials. *Neurorol Urodyn* 2009;28(4):320–4.
- [13] Nuhoglu B, Fidan V, Ayyıldız A, Ersoy E, Germiyanoglu C. Stoller afferent nerve stimulation in woman with therapy resistant over active bladder; a 1-year follow up. *Int Urogynecol J* 2006;17(3):204–7.
- [14] Van Der Pal F, Van Balken MR, Heesakkers JP, Debruyne FM, Bemelmans BL. Percutaneous tibial nerve stimulation in the treatment of refractory overactive bladder syndrome: is maintenance treatment necessary? *BJU Int* 2006;97(3):547–50.